Home

Brian Corvese

CIK 1393207 · last filed 2026-09-02

Brian Corvese is a corporate insider who has filed 51 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing shows the insider was granted $17.9K of INKT on Sep 2, 2026. Current disclosed insider exposure totals $689.2K across reported positions. 30 SEC filings were submitted jointly with AGENUS INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$689.2K

Companies

3

Total Filings

51

Lifetime Open-Market Net

$0

Filer Profile

Reported Address
C/O ANTIGENICS INC.
162 FIFTH AVENUE, SUITE 900
NEW YORK, NY 10010
Related Filers
AGENUS INC — 30 joint filings, latest 2026-08-11
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
INKT Director 54,770 $12.00 $657.2K $0 20 2026-09-02
AGEN Director 4,604 $6.94 $32.0K $0 28 2026-08-11
Protagenic Therapeutics, Inc.\new (PTIXW) Delisted Director — $0.01 — $0 1 2024-03-29

Recent Filings

51 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-02 INKT Grant (A) +1,633 $17.9K EDGAR
2026-08-11 AGEN Grant (A) — $0 EDGAR
2026-06-02 INKT Grant (A) +3,084 $35.8K EDGAR
2026-04-28 AGEN Grant (A) — $0 EDGAR
2026-01-06 INKT Grant (A) — $0 EDGAR
2025-12-03 INKT Grant (A) +1,612 $17.9K EDGAR
2025-09-11 INKT Grant (A) — $0 EDGAR
2025-09-03 INKT Grant (A) +1,290 $17.9K EDGAR
2025-06-20 AGEN Grant (A) — $0 EDGAR
2025-06-04 INKT Grant (A) +2,494 $17.9K EDGAR
Showing 1–10 of 51
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.